$585.01▾ 0.47%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$1.53cash per $1 profit
Strong
It turns every reported profit-dollar into real cash, and then some.
Valuation
73th pctvs its own history
Rich
Its valuation sits in the richer end of its own recent range.
Revenue growth
+17.2%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
Value-trap risk
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Medpace Holdings, Inc. turns 153¢ of every reported profit-dollar into real cash. Revenue is growing strongly year over year. Its valuation sits in the richer end of its own recent range.
Key numbers
Valuation
EPS (TTM)$17.03
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin17.7%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$2.78B
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days29 articles
18 bullish11 neutral0 bearish
[Latest] Global gRNA Market Size/Share Worth USD 2950 Million by 2034 at a 19% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision Medicine
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?
VHT vs. PBE: Which Health Care ETF Is the Better Buy?
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.